- Home
- SPRO vs STRS Comparison
SPRO vs STRS Comparison
Compare SPRO & STRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- STRS
- Stock Information
- Founded
- SPRO 2013
- STRS 1992
- Country
- SPRO United States
- STRS United States
- Employees
- SPRO N/A
- STRS N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- STRS Homebuilding
- Sector
- SPRO Health Care
- STRS Real Estate
- Exchange
- SPRO Nasdaq
- STRS Nasdaq
- Market Cap
- SPRO 164.4M
- STRS 155.7M
- IPO Year
- SPRO 2017
- STRS N/A
- Fundamental
- Price
- SPRO $2.91
- STRS $21.18
- Analyst Decision
- SPRO Buy
- STRS
- Analyst Count
- SPRO 4
- STRS 0
- Target Price
- SPRO $5.00
- STRS N/A
- AVG Volume (30 Days)
- SPRO 1.6M
- STRS 17.9K
- Earning Date
- SPRO 08-04-2025
- STRS 08-12-2025
- Dividend Yield
- SPRO N/A
- STRS N/A
- EPS Growth
- SPRO N/A
- STRS N/A
- EPS
- SPRO N/A
- STRS N/A
- Revenue
- SPRO $44,584,000.00
- STRS $32,719,000.00
- Revenue This Year
- SPRO N/A
- STRS N/A
- Revenue Next Year
- SPRO N/A
- STRS N/A
- P/E Ratio
- SPRO N/A
- STRS N/A
- Revenue Growth
- SPRO N/A
- STRS N/A
- 52 Week Low
- SPRO $0.51
- STRS $15.10
- 52 Week High
- SPRO $3.09
- STRS $30.66
- Technical
- Relative Strength Index (RSI)
- SPRO 71.62
- STRS 59.33
- Support Level
- SPRO $2.79
- STRS $18.50
- Resistance Level
- SPRO $3.03
- STRS $19.61
- Average True Range (ATR)
- SPRO 0.12
- STRS 1.11
- MACD
- SPRO -0.08
- STRS 0.12
- Stochastic Oscillator
- SPRO 43.75
- STRS 100.00
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About STRS Stratus Properties Inc.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.